Galectin Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $126.72 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Galectin Therapeutics Inc had its IPO on 2002-09-09 under the ticker symbol GALT.
The company operates in the Healthcare sector and Biotechnology industry. Galectin Therapeutics Inc has a staff strength of 9 employees.
Shares of Galectin Therapeutics Inc opened at $2.06 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $2.05 - $2.2, and closed at $2.17.
This is a +5.34% increase from the previous day's closing price.
A total volume of 102,942 shares were traded at the close of the day’s session.
In the last one week, shares of Galectin Therapeutics Inc have increased by +10.15%.
Galectin Therapeutics Inc's Key Ratios
Galectin Therapeutics Inc has a market cap of $126.72 million, indicating a price to book ratio of 207.6975 and a price to sales ratio of 0.
In the last 12-months Galectin Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Galectin Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Galectin Therapeutics Inc’s operating margin was 0% while its return on assets stood at -78.51% with a return of equity of -3727.95%.
In Q3, Galectin Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Galectin Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.6 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Galectin Therapeutics Inc’s profitability.
Galectin Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.4121. Its price to sales ratio in the trailing 12-months stood at 0.
Galectin Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $17.91 million
- Total Liabilities
- $9.59 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Galectin Therapeutics Inc ended 2023 with $17.91 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.91 million while shareholder equity stood at $-22335000.00.
Galectin Therapeutics Inc ended 2023 with $850000.00 in deferred long-term liabilities, $9.59 million in other current liabilities, 59000.00 in common stock, $-298868000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.83 million and cash and short-term investments were $15.83 million. The company’s total short-term debt was $39,000 while long-term debt stood at $29.73 million.
Galectin Therapeutics Inc’s total current assets stands at $17.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.35 million and inventory worth $0.
In 2023, Galectin Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Galectin Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Galectin Therapeutics Inc stock is currently trading at $2.17 per share. It touched a 52-week high of $2.57 and a 52-week low of $2.57. Analysts tracking the stock have a 12-month average target price of $11.
Its 50-day moving average was $1.71 and 200-day moving average was $1.58 The short ratio stood at 16.01 indicating a short percent outstanding of 0%.
Around 4005.2% of the company’s stock are held by insiders while 1209.5% are held by institutions.
Frequently Asked Questions About Galectin Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company’s lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.